Skip to content
Selurampanel
Selurampanel is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Migraine disordersD008881EFO_0003821G43—2———2
Adrenocortical adenomaD018246—1———1
Endometrial stromal sarcomaD018203—1———1
Multiple sclerosisD009103EFO_0003885G35—1———1
EpilepsyD004827EFO_0000474G40.9—1———1
SeizuresD012640G40.4—1———1
Reflex epilepsyD020195EFO_1001146—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSELURAMPANEL
INNselurampanel
Description
Selurampanel (INN, code name BGG492) is a drug closely related to the quinoxalinedione series which acts as a competitive antagonist of the AMPA and kainate receptors and, as of 2015, is being investigated in clinical trials by Novartis for the treatment of epilepsy. It has also been studied in the acute treatment of migraine, and was found to produce some pain relief, but with a relatively high rate of side effects.
Classification
Small molecule
Drug classionotropic non-NMDA (N-methyl D-aspartate) glutamate receptors [AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor) and/or KA (kainite antagonist) receptors]: antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)c1cc2[nH]c(=O)n(NS(C)(=O)=O)c(=O)c2cc1-c1ccnn1C
Identifiers
PDB—
CAS-ID912574-69-7
RxCUI—
ChEMBL IDCHEMBL3545042
ChEBI ID—
PubChem CID45381907
DrugBankDB12367
UNII ID7WG1MR7DAR (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 21 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
16 adverse events reported
View more details